Recent Settlements
Zwerling, Schachter & Zwerling prides itself on obtaining the very best results for its clients. Below find the latest verdicts and settlements in some of our more recent and notable cases.
Certain parties have reached a partial settlement of this Action, pending in the United States District Court for the District of New Jersey. The settlement provides for the payment of $7.9 million for the benefit of eligible Class Members.
The class shall consist of all persons and entities in the United States (including its territories) who, between January 1, 1997 through June 15, 2023, purchased or renewed a Contract of Insurance with any Lloyd’s Syndicates named as a Defendant in the Action. Excluded from the Settlement Class are Released Defendants, Defendants formerly named as such in the Action, all Lloyd’s syndicates, Opt-outs, and judges presiding over the Action and their immediate families (the “Settlement Class”).
The settlement was preliminarily approved by the Court on July 10, 2023.
More information is available at www.SyndicateSettlement.com
Allergan Has Tentative Agreement to End Restasis Antitrust Case
Antitrust litigation over an alleged scheme by AbbVie Inc. subsidiary Allergan to delay generic versions of the dry-eye treatment Restasis was put on hold by a federal judge in Brooklyn while the company finalizes a settlement in principle that would bring the dispute to an end.
Residents of assisted living facilities operated by Aegis Senior Communities LLC (Aegis) will share in a settlement fund of $16.25 million awarded as part of a class action settlement approved by the United States District Court for the Northern District of California on August 23, 2021.
Pursuant to the Settlement Agreement, the Defendant has agreed to pay a gross Dlass Settlement Fund of $1.9 million in cash, in exchange for customary releases.
Several Lloyd’s of London syndicates have agreed to pay $22 million to settle class claims they were conspiring with insurance brokers to conceal exorbitant commissions and the anti-competitive nature of their market, according to a filing Friday in New Jersey federal court.